• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Athenex Inc.

    5/23/23 8:03:51 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNX alert in real time by email
    NT 10-Q 1 d425990dnt10q.htm NT 10-Q NT 10-Q

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

    SEC File Number: 001-38112

    CUSIP Number: 04685N202

     

    (Check one):      

    ☐  Form 10-K     ☐  Form 20-F     ☐  Form 11-K     ☒  Form 10-Q

    ☐  Form 10-D     ☐  Form N-CEN     ☐  Form N-CSR

      For Period Ended:  March 31, 2023
      ☐  Transition Report on Form 10-K
      ☐  Transition Report on Form 20-F
      ☐  Transition Report on Form 11-K
      ☐  Transition Report on Form 10-Q
      For the Transition Period Ended:     

     

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

          

     

    PART I — REGISTRANT INFORMATION

    Athenex, Inc.

    Full Name of Registrant

    N/A

    Former Name if Applicable

    1001 Main Street, Suite 600

    Address of Principal Executive Office (Street and Number)

    Buffalo, New York 14203

    City, State and Zip Code

     

     

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

     
    ☐      (a)  

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

      (b)  

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

    PART III — NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Athenex, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) within the prescribed time period or within the five day extension period permitted by the applicable rules of the Securities and Exchange Commission without unreasonable effort or expense.

    As previously disclosed, on May 14, 2023, the Company together with certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code (the “Code”) with the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). On the Petition Date, the Debtors filed a motion with the Bankruptcy Court seeking to jointly administer the Chapter 11 cases under the caption “In re: Athenex, Inc., et al.” (Case No. 23-90295) (the “Chapter 11 Case”).

    Due to the considerable time and resources that management has had to devote to the Chapter 11 Case and related obligations, and changes in the Company’s financial position, which would need to be reflected in the Company’s financial statements, the Company cannot, without unreasonable effort or expense, timely file the Form 10-Q. At this time, the Company cannot estimate when it will be able to file the Form 10-Q, if at all.

    The Debtors expect to continue to operate their businesses as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the provisions of the Code and the orders of the Bankruptcy Court. As a debtors-in-possession under the Code, the Debtors are required to file monthly operating reports with the Bankruptcy Court. The Company cautions that these monthly operating reports may include financial statements that are limited in scope and cover a limited time period. The monthly operating reports are filed solely for the purpose of complying with requirements applicable in the Chapter 11 Case, are in a format acceptable to the Bankruptcy Court, and are not prepared in accordance with U.S. generally accepted accounting principles. Existing and potential investors should not place undue reliance upon the information contained in such monthly operating reports, which are not prepared for the purpose of providing the basis for an investment decision relating to the Company’s common stock.

    The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Case.

     

     

    PART IV — OTHER INFORMATION

     

    (1)          Name and telephone number of person to contact in regard to this notification
            Joe Annoni                  (716)                  427-2950
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).   ☒    Yes  ☐    No
            
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  ☐  Yes  ☒    No
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

    Athenex, Inc.

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:    May 22, 2023              

    /s/ Joe Annoni

             

    Name:   Joe Annoni

             

    Title:     Chief Financial Officer

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

     

    ATTENTION

     

    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

     

     

     

    Get the next $ATNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNX

    DatePrice TargetRatingAnalyst
    10/12/2021$8.00 → $5.00Outperform
    RBC Capital
    8/6/2021$9.00 → $8.00Outperform
    RBC Capital
    8/6/2021$5.00 → $4.00Market Perform
    SVB Leerink
    More analyst ratings

    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

      To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX) ("Athenex" or the "Company"), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company's assets across its primary businesses: Athenex Pharmaceu

      5/14/23 11:15:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

      Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

      3/20/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Announces a Reverse Stock Split

      BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on November 22, 2022, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's common stock, at

      2/14/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Lau Johnson Yiu Nam

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:36:36 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Kwan Rudolf

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:33:18 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cook Timothy Devere

      4 - Athenex, Inc. (0001300699) (Issuer)

      5/8/23 4:29:48 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FAMOTIDINE issued to ATHENEX INC

      Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

      1/12/22 4:41:30 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KLISYRI

      Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

      12/20/20 4:30:55 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    SEC Filings

    See more
    • Athenex Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      10/2/23 7:42:29 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Inc. filed SEC Form 8-K: Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      8/17/23 4:06:01 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Leadership Update

      8-K - Athenex, Inc. (0001300699) (Filer)

      7/18/23 9:03:58 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on Athenex with a new price target

      RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $5.00 from $8.00 previously

      10/12/21 6:58:34 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Athenex with a new price target

      RBC Capital reiterated coverage of Athenex with a rating of Outperform and set a new price target of $8.00 from $9.00 previously

      8/6/21 9:52:27 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Athenex with a new price target

      SVB Leerink reiterated coverage of Athenex with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously

      8/6/21 5:46:15 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Financials

    Live finance-specific insights

    See more

    $ATNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

      Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-502 CAR-NKT cell therapy product anticipated in 2H 2023 Phase 1 GINAKIT2 study of KUR-501 on clinical hold; pending serious adverse event investigation and safety risk mitigation planning

      3/20/23 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

      BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time. To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins: Domestic: 1-844-826-3033 International: 1-412-317-5185 Pass

      10/24/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Provides Second Quarter 2022 Financial Results and Business Update

      Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respectivelyMaintains full-year 2022 product revenue guidance range of 20-25% growth year-over-year Management to host conference call and webcast today at 8:00 a.m. EDT BUFFALO, N.Y.

      7/28/22 7:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

      BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. "We are delighted to welcome Dr. Cohen to Athenex during this transformative period, as we strategically pivot to focus on advancing first-in-class

      6/8/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athenex Announces Appointment of Chief Financial Officer

      BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity, investment banking, and Big4 Advisory, with over 20 years of corporate finance experience. "The Board of Directors joins me in welcoming Joe to his new position as CFO," said Johnson Lau, Chief

      2/22/22 8:00:00 AM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Athenex Inc. (Amendment)

      SC 13D/A - Athenex, Inc. (0001300699) (Subject)

      2/14/23 4:10:55 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Athenex Inc.

      SC 13D - Athenex, Inc. (0001300699) (Subject)

      2/2/23 5:01:53 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Athenex Inc. (Amendment)

      SC 13G/A - Athenex, Inc. (0001300699) (Subject)

      2/14/22 3:50:00 PM ET
      $ATNX
      Biotechnology: Pharmaceutical Preparations
      Health Care